KAILERA THERAPEUTICS INC (KLRA)
Health Care · Biotechnology · NASDAQ
Kailera Therapeutics is a clinical-stage biotechnology company advancing a diversified pipeline of GLP-1-based therapies for the treatment of obesity.
What KAILERA THERAPEUTICS INC does
Kailera Therapeutics is a clinical-stage biotechnology company focused on the development of obesity management medications. Its pipeline consists of GLP-1-based therapeutic candidates, including dual and tri-agonists, aimed at addressing weight loss and related metabolic conditions through both injectable and oral delivery methods. The company operates through a strategic license and collaboration agreement with Jiangsu Hengrui Pharmaceuticals for the development and commercialization of its product candidates outside of Greater China.
Themes: obesity / weight loss drugs, GLP-1 receptor agonists, metabolic disease, GIP receptor dual agonists, triple receptor agonists
Fundamentals
- Price$16.54 as of 2026-08-24 close
- Market cap$2.1B as of 2026-08-24
- P/En/a earnings data not available
- ROE-23.4% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta2.14 as of 2026-08-24
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How KLRA compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How KAILERA THERAPEUTICS INC looks technically
KAILERA THERAPEUTICS INC (KLRA): there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative). It just made a new 20-day low, breaking below its recent trading range.
Trend
8
| Distance from the 200-day | not enough price history yet — needs 200 trading sessions | n/a |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $19.15 | $19.15 |
| 200-day moving average | not enough price history yet — needs 200 trading sessions | n/a |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 13 calendar days ago — the swings before that are what the structure reading is measured on | 13 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 19.51. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | not enough price history yet — needs 200 trading sessions | n/a |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend) | 15.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30) | 36.5 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($16.37 to $19.51) — its "stochastic" reading is 5 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 5.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $28.23 | $28.23 |
|---|---|---|
| From the 52-week high | it is 41.4% below its 52-week high (its highest price of the past year) | -41.4% |
| Above the 52-week low | it is 1.0% above its 52-week low (its lowest price of the past year) | +1.0% |
| Below the 52-week high | it is 41.4% below its highest point of the past year | 41.4% |
| Since a 20-day breakout | it just made a new 20-day low, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $28.23 (set on 2026-04-20) | $28.23 |
| Given back of the 52-week move | not available for this company yet | n/a |
| From the all-time high | it is 41.4% below its all-time high | -41.4% |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $16.37 (set on 2026-08-24) | $16.37 |
| Above the all-time low | it is 1.0% above its all-time low | +1.0% |
Volatility
4
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 83% of it) | 17th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.14 between its high and its low — about 6.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.14 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $16.32 and $19.37 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $16.32 – $17.85 – $19.37 |
| Typical daily range (% of price) | its price moves about 6.9% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.9% |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.08× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.5% since the prior reading | -0.5% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-24 0.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.2% |
|---|---|---|
| Gap filled | a 2.3% gap up opened on 2026-07-27 has been "filled" 20 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 20 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -9.72% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 9.8 percentage points (the stock lost 6.5% while the market gained 3.3%) | -9.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 24.3 percentage points (the stock lost 21.9% while the market gained 2.4%) | -24.3% |
| vs market, 6 months | not available for this company yet | n/a |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 1 of the 6 technical signals we can compute for it is currently in a bullish state: near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 1 of 6 |
|---|---|---|
| Bearish technical signals | 3 of the 6 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 6 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 20% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-17 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 13.3% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -20.2% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 23% below the average price paid since 2026-04-17, so the typical buyer over that stretch is under water. That average is $21.50 — a volume-weighted average of daily closes over 79 sessions, not a true tick-by-tick VWAP. | -23.1% |
|---|
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $19.51.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $7.48 and $12.08 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $19.51.
This reading has stood for 5 trading days, since 2026-08-18.
Read from daily closes as of 2026-08-24.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Broke down to a new 20-day low · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) · Most volatile (6%+ typical daily range) · At the bottom of its 14-day range (stochastic below 20) · Trading below the Ichimoku cloud | Learn: adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-24. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.17 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$42.40 range $30.00 – $57.00; median $41.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for KLRA
- Consensus EPS estimate-$1.07 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["All product candidates are in clinical development, and there is no guarantee of regulatory approval or commercial success.","Reliance on a single strategic collaboration with Jiangsu Hengrui Pharmaceuticals for the development and supply of its product candidates.","Lack of head-to-head clinical trial data against currently approved obesity therapies."]
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days5 buys ($327M) · 0 sells — 5 buying insiders
Cluster buying: 5 different insiders reported open-market purchases (SEC code P) of KLRA within a 30-day window between 2026-04-20 and 2026-04-20. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Most recent open-market transaction: 2026-04-20. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about KLRA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
KLRA had 6,626,235 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
KLRA had 5.11% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 13.23 days to cover at the same settlement.
- Reported short interest (shares) 6,626,235
- Short interest (% of shares outstanding) 5.11%
- Prior settlement (shares) 6,413,693
- Reported change 3.31%
- Days to cover (reported) 13.23
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Eli Lilly (LLY)
- Novo Nordisk (NVO)
- Viking Therapeutics (VKTX)
- Altimmune (ALT)
- Structure Therapeutics (GPCR)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare KLRA vs…
Frequently asked questions
What does KAILERA THERAPEUTICS INC (KLRA) do?
Kailera Therapeutics is a clinical-stage biotechnology company focused on the development of obesity management medications. Its pipeline consists of GLP-1-based therapeutic candidates, including dual and tri-agonists, aimed at addressing weight loss and related metabolic conditions through both injectable and oral delivery methods.
What sector is KAILERA THERAPEUTICS INC (KLRA) in?
KAILERA THERAPEUTICS INC (KLRA) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are KAILERA THERAPEUTICS INC's (KLRA) competitors?
Notable peers of KAILERA THERAPEUTICS INC (KLRA) include Eli Lilly, Novo Nordisk, Viking Therapeutics, Altimmune and Structure Therapeutics. This peer set is informational only — not financial advice.
Is KAILERA THERAPEUTICS INC (KLRA) overbought or oversold right now?
KAILERA THERAPEUTICS INC (KLRA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 36, in the neutral middle (as of 2026-08-24). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on KLRA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.